Loading...
•
Mar 31, 2021
Marinus Pharmaceuticals Q1 2021 Earnings Report
Marinus Pharmaceuticals reported financial results for Q1 2021 and provided a business update.
Key Takeaways
Marinus Pharmaceuticals announced an agreement with Oaktree for up to $125 million in credit financing to support commercial, clinical, and next-generation formulations. The company is progressing with clinical programs and targeting NDA submission for ganaxolone in CDKL5 deficiency disorder by mid-2021.
Reached agreement with Oaktree to secure up to $125 million in credit financing.
Targeting NDA submission to the FDA for ganaxolone in CDKL5 deficiency disorder by mid-2021.
Phase 2 clinical trial in tuberous sclerosis complex expected to be completed this summer.
Top-line data expected for the Phase 3 RAISE trial in refractory status epilepticus in the first half of 2022.
Marinus Pharmaceuticals
Marinus Pharmaceuticals
Forward Guidance
Marinus Pharmaceuticals is focused on commercial preparedness for potential product launch in the U.S., continued enrollment in Phase 3 trial in RSE, and planned initiation of a Phase 3 trial in TSC.